Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

PetVivo Holdings Q2 2026 Results: Net Loss of $1.95M, Loss Narrows

PetVivo Holdings reported a net loss of $3,560,419 for the six months ended September 30, 2026, compared to $4,555,587 in the prior year period. Revenues decreased slightly to $550,377, while the company experienced a significant reduction in cash to $16,287 and a total stockholders' deficit of $159,093.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue0.20.3
Gross profit0.20.2
Profit before tax-1.9-2.2
Net income-1.9-2.2
EPS (diluted, $ a share)$-0.05$-0.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-29.8%
Gross margin92.1%
Source

10-Q filed with the SEC, OTC: PETV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

PetVivo Holdings, Inc.: key numbers

Share price
$0.5150Close, Nov 16
Market cap
$19.8M
Shares outstanding
38.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from PetVivo Holdings, Inc.

All →
7:01 AM ET 8-K
Leadership Change

PetVivo Holdings Leadership Change

PetVivo Holdings announced the appointment of Jaime K. Pickett to its Board of Directors, effective September 22, 2026, filling a vacancy created by the resignation of Diane Levitan. Dr. Pickett brings over 20 years of experience in veterinary healthcare and executive leadership, including former roles as CEO and President of Hannah Pet Hospitals.

7:01 AM ET 8-K
Leadership Change

PetVivo Holdings Leadership Change

Joseph Jasper resigned from the Board of Directors of PetVivo Holdings, Inc., effective September 22, 2026. To fill the vacancy, the Board appointed Michael K. Handley, a life sciences executive with over 25 years of experience in biotechnology and medical devices, as a non-employee director. Handley's background includes raising over $700 million in capital and supporting more than 80 global product launches.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.